Literature DB >> 15665308

Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency.

Tae Woo Kim1, Jin-Hyup Lee, Liangmei He, David A K Boyd, J Marie Hardwick, Chien-Fu Hung, T-C Wu.   

Abstract

RNA interference using small interfering RNA (siRNA) is an effective means of silencing gene expression in cells. Intradermal administration of nucleic acids via gene gun represents an efficient method for delivering nucleic acids to professional antigen-presenting cells in vivo. In this study, we show that the coadministration of DNA vaccines encoding human papillomavirus type 16 E7 with siRNA targeting key proapoptotic proteins Bak and Bax prolongs the lives of antigen-expressing dendritic cells in the draining lymph nodes, enhances antigen-specific CD8(+) T-cell responses, and elicits potent antitumor effects against an E7-expressing tumor model in vaccinated mice. Our data indicate that intradermal administration of siRNA to manipulate gene expression represents a plausible strategy for modification of the properties of professional antigen-presenting cells in vivo to enhance cancer vaccine potency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665308

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

2.  Regulation of the lifespan in dendritic cell subsets.

Authors:  Min Chen; Li Huang; Zainuer Shabier; Jin Wang
Journal:  Mol Immunol       Date:  2007-01-30       Impact factor: 4.407

Review 3.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

4.  Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR.

Authors:  Tianhong Wang; Qiong Jiang; Camie Chan; Kevin S Gorski; Erin McCadden; David Kardian; Drew Pardoll; Katharine A Whartenby
Journal:  Blood       Date:  2009-01-22       Impact factor: 22.113

Review 5.  RNA interference: a potent technology in studying and modulating of dendritic cells, and potential in clinical therapy.

Authors:  Fang Cheng; Song He
Journal:  Mol Biol Rep       Date:  2009-09-12       Impact factor: 2.316

6.  A novel cancer therapeutic using thrombospondin 1 in dendritic cells.

Authors:  Tzu-Yang Weng; Shih-Shien Huang; Meng-Chi Yen; Chi-Chen Lin; Yi-Ling Chen; Chiu-Mei Lin; Wei-Ching Chen; Chih-Yang Wang; Jang-Yang Chang; Ming-Derg Lai
Journal:  Mol Ther       Date:  2013-10-15       Impact factor: 11.454

Review 7.  DC-based cancer vaccines.

Authors:  Eli Gilboa
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Sustained long-term RNA interference in nucleus pulposus cells in vivo mediated by unmodified small interfering RNA.

Authors:  Teppei Suzuki; Kotaro Nishida; Kenichiro Kakutani; Koichiro Maeno; Takashi Yurube; Toru Takada; Masahiro Kurosaka; Minoru Doita
Journal:  Eur Spine J       Date:  2009-01-14       Impact factor: 3.134

Review 9.  Therapeutic human papillomavirus vaccines: current clinical trials and future directions.

Authors:  Chien-Fu Hung; Barbara Ma; Archana Monie; Shaw-Wei Tsen; T-C Wu
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

10.  RNAi and cancer: Implications and applications.

Authors:  Maen Abdelrahim; Stephen Safe; Cheryl Baker; Ala Abudayyeh
Journal:  J RNAi Gene Silencing       Date:  2006-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.